PCI-24781, a Novel Hydroxamic Acid HDAC Inhibitor, Exerts Cytotoxicity and Histone Alterations via Caspase-8 and FADD in Leukemia Cells

Histone deacetylase inhibitors (HDACi) have become a promising new avenue for cancer therapy, and many are currently in Phase I/II clinical trials for various tumor types. In the present study, we show that apoptosis induction and histone alterations by PCI-24781, a novel hydroxamic acid-based HDAC...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Rivera-Del Valle, Nilsa, Gao, Shan, Miller, Claudia P., Fulbright, Joy, Gonzales, Carolina, Sirisawad, Mint, Steggerda, Susanne, Wheler, Jennifer, Balasubramanian, Sriram, Chandra, Joya
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Hindawi Publishing Corporation 2010
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2817379/
https://ncbi.nlm.nih.gov/pubmed/20145726
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2010/207420
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller